Performance of a Diagnostic Algorithm for Functional Gastrointestinal Disorders - European Medical Journal

Performance of a Diagnostic Algorithm for Functional Gastrointestinal Disorders

2 Mins
Ecushla C. Linedale,1 Antonina Mikocka-Walus,2 Andrew D. Vincent,1 Peter R. Gibson,3,4 *Jane M. Andrews1,5

Dr Andrews has served as a speaker, a consultant, and/or an advisory board member for Abbott, AbbVie, Allergan, Celgene, Ferring, Takeda, MSD, Shire, Janssen, Hospira, and Pfizer, and has received research funding from Abbott, AbbVie, Ferring, MSD, Shire, and Janssen. Dr Gibson has served as a consultant or advisory board member for AbbVie, Ferring, Janssen, Merck, Nestle Health Science, Danone, Allergan, Pfizer, and Takeda. His institution has received speaking honoraria from AbbVie, Janssen, Ferring, Takeda, Fresenius Kabi, Mylan, and Pfizer. He has received research grants for investigator-driven studies from AbbVie, Janssen, Falk Pharma, Danone, the a2 Milk Company. His department financially benefits from the sales of a digital application and booklets on the low-FODMAP diet. He has published an educational/recipe book on diet. Dr Linedale was supported by The University of Adelaide, Adelaide, Australia, PhD Scholarship. Antonina Mikocka-Walus and Andrew Vincent declare no conflicts of interest. The faecal tests used in this study were supported by untied funding from Abbott Pathology, Adelaide, Australia.

EMJ Gastroenterol. ;6[1]:47-48. Abstract Review No. AR6.
Diagnosis, functional dyspepsia, functional gastrointestinal disorders, irritable bowel syndrome, management, primary care

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Functional gastrointestinal disorders (FGID), such as irritable bowel syndrome and functional dyspepsia, are poorly managed in many healthcare settings. Delays in diagnosis and the unnecessary use of invasive investigations are common. Although symptom-based diagnostic criteria and effective evidence-based treatments are available, most clinicians outside FGID specialist centres do not use these criteria in practice and are not confident in diagnosing without specialist input. In fact, gastroenterology referrals for suspected FGID can represent up to half of ambulatory gastroenterology consultations and often exceed the capacity of publicly funded tertiary referral centres. This results in not only extremely long waiting lists but also poor patient outcomes and high use of healthcare resources due to delayed diagnosis and the lack of effective management.

The aim of this study was to determine whether an alternative model of care could be used to facilitate a safe and timely diagnosis and provide effective management without direct specialist input. Participants from the routine waiting list of a tertiary referral centre were randomised to a waiting list control group or algorithm group (1:2). A total of 315 patients were invited, with 109 completing intake (control n=20, algorithm n=89). Participants in the algorithm group were screened with a questionnaire and routine tests (without consultation). Almost two in five patients (39%) had clinical signs requiring a gastroenterologist review, which resulted in prompt detection of organic disease in almost a third. Organic diseases diagnosed during the study included inflammatory bowel disease, neoplasm, pancreatic insufficiency, reflux oesophagitis, and iron deficiency, the cause of which was unknown. Half of those screened had no clinical warning signs and received a letter clearly stating and explaining the FGID diagnosis. Information about FGID and evidence-based management options, such as the low FODMAP diet (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols), and psychological therapies, as well as resources and how to access these services, was also provided to both the patient and referring doctor.

All but one participant read the diagnostic letter, and those who read it found it to be useful because it provided a diagnosis, reassurance, and management options. Interestingly, only a quarter of patients discussed the letter with their physician, yet most (80%) engaged in some form of management regime by 6 weeks post-diagnosis. Dietary management options were used almost twice as often as psychological therapies, and do-it-yourself options were preferred. Symptomatic improvement was reported in 61% of respondents at 6 weeks, and 86% at 1 year post-diagnosis. The approach was at least moderately acceptable to 68% of participants and 100% of referring doctors. The preference for self-management options identifies an important opportunity to safely address a clear clinical need. Similarly, the poorer uptake of psychological therapies, such as gut-directed hypnotherapy, which have been shown to be very effective in reducing global symptom burden, highlights the need for better communication regarding the brain-gut axis and the ability to harness this to achieve symptomatic improvement.

This study has shown that a simple screening algorithm can be used to improve the detection of organic disease and provide timely, accurate diagnosis of and evidence-based management options for FGID without gastroenterologist consultation. This pathway has been shown to be safe and, importantly, safer than current triaging of referrals. The process was feasible to implement and acceptable to both patients and doctors.  These pilot data are encouraging and justify a further larger scale evaluation within primary care.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?